NEW YORK, June 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=153517&from=4CLASS PER ...

Leadership Transition - Iovance Biotherapeutics Inc. announced the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025, to pursue other endeavors [1][2] - Bellemin's departure coincides with the company's struggles, including a commercial setback for its flagship drug, Amtagvi, and a class-action securities lawsuit [1][3] Commercial Performance - Iovance's first-quarter sales for Amtagvi significantly underperformed Wall Street expectations, leading to a revision of full-year revenue projections [3] - Following the disappointing results and revenue guidance revision, Iovance's stock fell over 44%, from $3.17 per share on May 8, 2025, to $1.75 per share by the close of trading on May 9, 2025 [6][7] Legal Challenges - Iovance is facing a securities fraud class action lawsuit related to the company's portrayal of its authorized treatment centers (ATCs), which are essential for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Market Reaction - The market reacted negatively to the company's underwhelming first-quarter results and the downward revision of revenue guidance, attributing the issues to slow treatment timelines and inefficiencies in patient selection [6][7] - Hagens Berman is investigating the allegations and scrutinizing whether Iovance's public statements aligned with internal realities [8]

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and its senior executives for potential violations of federal securities laws, following disappointing financial results and issues with its key melanoma treatment, Amtagvi [1][2][5]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. Product Launch and Issues - Iovance launched its key melanoma treatment, Amtagvi, in February 2024, but has faced challenges with its authorized treatment centers (ATCs) [3]. - The company claimed that its ATCs would drive demand for Amtagvi; however, there were long timelines for patient treatment initiation and ineffective patient identification, leading to high patient drop-off rates [4]. Financial Performance - On May 8, 2025, Iovance reported disappointing financial results for the first quarter of 2025 and revised its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off rates as contributing factors [5]. - Following the announcement of these results, Iovance's stock price fell over 44%, from $3.17 per share to $1.75 per share within a day [6].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that Iovance provided misleading positive statements while concealing adverse facts about its growth potential and ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of patient treatments [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of false and misleading statements regarding the company's growth potential and operational capabilities [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $100,000 in Iovance between August 8, 2024, and May 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Iovance and its executives violated federal securities laws by failing to disclose the true state of the company's growth potential and operational readiness [4]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced a reduction in its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace in treatment initiation [5]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [5].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, particularly related to the company's performance and treatment timelines for its melanoma drug Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs in driving demand for Amtagvi, while in reality, the ATCs faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - The company reported disappointing financial results for Q1 2025, revising its full-year 2025 revenue guidance downward, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - Following the announcement of poor financial results, Iovance's stock price fell over 44%, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading positive statements while concealing material adverse facts about its growth potential, particularly its inability to generate demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Iovance Biotherapeutics, Inc. faces a class action lawsuit following a significant decline in its financial performance and misleading statements regarding its business operations and revenue guidance [1][2][3]. Financial Performance - For Q1 2025, Iovance reported total product revenue of $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of approximately 33% [2]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2]. Lawsuit Details - The class action lawsuit alleges that Iovance made materially false and misleading statements and failed to disclose adverse facts about its business, including delays in treatment timelines at new Authorized Treatment Centers (ATCs) and inefficiencies in patient identification and selection [3]. - The complaint highlights that these issues led to increased costs and lower revenue, contradicting the company's positive statements about its operations and prospects [3]. Legal Action - Investors who purchased Iovance securities during the specified Class Period (May 9, 2024, to May 8, 2025) have until July 14, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/iovance-biotherapeutics-inc- ...